SCHEMBL3325835

SCHEMBL3325835

NS(=O)(=O)c1ccc(C(=O)OCCN2CCCCC2)cc1

nearest known ligand 0.68

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.68
MEN1 O00255 2/20 0.68
HRH3 Q9Y5N1 6/20 0.63
KCNH2 Q12809 3/20 0.63
CYP2D6 P10635 1/20 0.58
CA12 O43570 4/20 0.54
CA1 P00915 4/20 0.54
CA2 P00918 4/20 0.54
CA9 Q16790 4/20 0.54
CA14 Q9ULX7 3/20 0.54
CA7 P43166 2/20 0.54
CA4 P22748 1/20 0.52
TSHR P16473 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3322597 0.99 KMT2A (0.66) KMT2AMEN1HRH3KCNH2CYP2D6
SCHEMBL3326110 0.92 CYP2D6 (0.70) KMT2AMEN1HRH3KCNH2CYP2D6
SCHEMBL3327501 0.91 CYP2D6 (0.67) KMT2AMEN1HRH3KCNH2CYP2D6
SCHEMBL14178128 0.82 HRH3 (0.48) KMT2AMEN1HRH3KCNH2CYP2D6
Hydrochloric Acid SCHEMBL11644656 0.82 KMT2A (0.74) KMT2AMEN1HRH3KCNH2CYP2D6
SCHEMBL14106811 0.81 KMT2A (1.00) KMT2AMEN1HRH3KCNH2CYP2D6
SCHEMBL11645996 0.81 KMT2A (0.73) KMT2AMEN1HRH3CYP2D6TSHR
SCHEMBL14066338 0.80 KMT2A (0.76) KMT2AMEN1HRH3KCNH2CYP2D6
SCHEMBL21705256 0.80 KMT2A (0.76) KMT2AMEN1HRH3KCNH2CYP2D6
SCHEMBL501868 0.80 KMT2A (0.75) KMT2AMEN1CYP2D6TSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142499-B1 Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use for treating glaucoma UNIMED PHARMA SPOL SRO (SK) 2014-12-10 EP claimed
US-8193184-B2 Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use Unimed Pharma, SPOL, S.R.O. (SK) 2012-06-05 US claimed
US-20100125076-A1 SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2010-05-20 US claimed
EP-2142499-A1 SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE Unimed Pharma, Spol. S R.O. (SK) 2010-01-13 EP claimed
WO-2008130332-A1 SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2008-10-30 WO claimed
EP-2142499-B1 Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use for treating glaucoma UNIMED PHARMA SPOL SRO (SK) 2014-12-10 EP disclosed
US-8193184-B2 Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use Unimed Pharma, SPOL, S.R.O. (SK) 2012-06-05 US disclosed
US-20100125076-A1 SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2010-05-20 US disclosed
EP-2142499-A1 SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE Unimed Pharma, Spol. S R.O. (SK) 2010-01-13 EP disclosed
WO-2008130332-A1 SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125076-A1 SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE ARSA, SMS, SULT1E1 KMT2A 1249/4885MEN1 3811/4885HRH3 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.